HROW - PRICE - Harrow, Inc.

Mark Baum is effectively growing the business in the ophthalmic drug segment, leveraging expansion through its own distribution system. Harrow, Inc. (HROW) revenues are based on dominance in the US prescription drop niche and the market launch of Vevye and Iheezo, with the indicator standing at 32.95. This price chart reflects the dynamics of an asset growing through the aggressive acquisition of rights to third-party drugs and their subsequent scaling.

The investment attractiveness of Harrow, Inc. (HROW) depends on the company's ability to monetize its ophthalmology brands and in-house manufacturing. The price reflects the current market consensus on the value of a single share, formed through the mechanism of supply and demand. By analyzing this price chart, an investor determines the entry point by comparing quotes with the potential for expanding market share in dry eye treatments. This price action visualizes the balance between risks and the expected return on capital.